
In Vivo CAR-T Therapy SNC116 Completes First Patient Enrollment
Shenogen Biotechnology's in vivo CAR-T product SNC116 targeting CD19 initiated clinical research at the Cancer Hospital of the Chinese Academy of Medical Sciences and completed enrollment of the first patient. It aims to solve accessibility issues associated with traditional CAR-T therapies.
Cancer Hospital, Chinese Academy of Medical Sciences